Articles from BlossomHill Therapeutics, Inc.

BlossomHill Therapeutics, Inc., a privately-held, clinical-stage biotechnology company focused on the design and development of small molecule medicines for treating cancer and autoimmune diseases, today announced the first cohort of patients has been dosed in the SOLARA study (NCT06706076). SOLARA is a global, open label, dose escalation and expansion Phase 1/2 clinical trial assessing the safety, efficacy and tolerability of BH-30643 for locally advanced or metastatic non-small cell lung cancer (NSCLC) bearing EGFR or HER2 mutations.
By BlossomHill Therapeutics, Inc. · Via Business Wire · January 22, 2025

BlossomHill Therapeutics, Inc., a clinical-stage biotechnology company focused on the design and development of small molecule medicines for treating cancer and autoimmune diseases, today announced the appointment of Geoff Oxnard, M.D., as Chief Medical Officer and Executive Vice President. Dr. Oxnard is a globally recognized clinical and translational cancer investigator who spent nearly 10 years on faculty at the Dana-Farber Cancer Institute and Harvard Medical School. His research catalyzed many of the early clinical insights into sensitivity and resistance to EGFR inhibitors in advanced lung cancer, including the first description of the EGFR C797S resistance mutation, reported in Nature Medicine in 2015.
By BlossomHill Therapeutics, Inc. · Via Business Wire · January 6, 2025

BlossomHill Therapeutics, a biotechnology company focused on the design and development of small molecule medicines for treating cancer and autoimmune diseases, today announced Jingrong Jean Cui, Ph.D., Co-Founder, President and Chief Executive Officer of BlossomHill Therapeutics, has been elected to the National Academy of Engineering (NAE). The prestigious honor recognizes Dr. Cui’s direct role in the innovation of new medicines to fight cancer and address urgent medical needs.
By BlossomHill Therapeutics, Inc. · Via Business Wire · February 14, 2024